NEW YORK (GenomeWeb) – Proteomics International said today it has entered a strategic alliance with CPR Pharma Services focused on clinical trials and related research.
Under the terms of the deal, Proteomics International will acquire 10 percent of CPR's share capital in exchange for 4 million of its shares. This transaction is subject to CPR shareholder approval and is scheduled to take place on March 5, 2018.